866-997-4948(US-Canada Toll Free)

Melanoma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 195 Pages


Global Markets Directs, \'Melanoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Melanoma. 

Melanoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Melanoma.
  • A review of the Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Melanoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Melanoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Melanoma Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Melanoma 12
Melanoma Therapeutics under Development by Companies 14
Melanoma Therapeutics under Investigation by Universities/Institutes 24
Late Stage Products 28
Comparative Analysis 28
Mid Clinical Stage Products 29
Comparative Analysis 29
Early Clinical Stage Products 30
Comparative Analysis 30
Discovery and Pre-Clinical Stage Products 31
Comparative Analysis 31
Melanoma Therapeutics – Products under Development by Companies 32
Melanoma Therapeutics – Products under Investigation by Universities/Institutes 43
Companies Involved in Melanoma Therapeutics Development 47
Johnson & Johnson 47
Vical Incorporated 48
Amgen Inc. 49
AstraZeneca PLC 50
Eli Lilly and Company 51
Viralytics Ltd. 52
GlaxoSmithKline plc 53
Nektar Therapeutics 54
Antigenics, Inc. 55
Inovio Biomedical Corporation 56
medac GmbH 57
Merck & Co., Inc. 58
Lentigen Corporation 59
Generex Biotechnology Corporation 60
Plexxikon Inc. 61
Amorfix Life Sciences Ltd. 62
Prolexys Pharmaceuticals, Inc. 63
Aposense Ltd. 64
Histogen, Inc. 65
ZIOPHARM Oncology, Inc. 66
Novartis AG 67
Aphios Corporation 68
Daewoong Pharmaceutical Co., Ltd. 69
Eisai Co., Ltd. 70
Ono Pharmaceutical Co., Ltd. 71
Pfizer Inc. 72
SuperGen, Inc. 73
Teva Pharmaceutical Industries Limited 74
Hadasit Medical Research Services & Development Ltd 75
Exelixis, Inc. 76
Aduro BioTech 77
Alfacell Corporation 78
Bayer AG 79
MannKind Corporation 80
4SC AG 81
EpiCept Corporation 82
Hana Biosciences, Inc. 83
Celldex Therapeutics, Inc. 84
Anavex Life Sciences Corp. 85
Lorus Therapeutics Inc 86
Cleveland BioLabs, Inc. 87
Oncolytics Biotech Inc. 88
Compugen Ltd. 89
Patrys Limited 90
Curis, Inc. 91
La Jolla Pharmaceutical Company 92
Green Cross Corporation 93
Innocell Corporation 94
Synta Pharmaceuticals Corp. 95
Summit Corporation plc 96
Scancell Holdings Plc 97
MabVax Therapeutics, Inc. 98
Antigen Express, Inc. 99
Cancer Research Technology Limited 100
Digna Biotech, S.L. 101
Oryzon 102
PCI Biotech Holding ASA 103
Antisense Pharma GmbH 104
Bionucleon Srl 105
Ambit Biosciences Corporation 106
Philogen S.p.A. 107
Multimmune GmbH 108
Alethia Biotherapeutics Inc. 109
Hawthorn Pharmaceuticals, Inc. 110
MacroGenics, Inc. 111
PDS Biotechnology Corporation 112
AlphaVax, Inc. 113
Azaya Therapeutics, Inc. 114
Iconic Therapeutics, Inc. 115
ProNAi Therapeutics, Inc. 116
Jennerex Biotherapeutics, Inc. 117
Axelar AB 118
Pharminox Limited 119
Innogene Kalbiotech Pte Ltd. 120
NovaLead Pharma Pvt. Ltd. 121
Welichem Biotech Inc. 122
Vaccinogen, Inc. 123
APEIRON Biologics AG 124
NewLink Genetics Corporation 125
SBI Biotech Co., Ltd. 126
InteRNA Technologies B.V. 127
Cellceutix Corporation 128
Avir Green Hills Biotechnology AG 129
TVAX Biomedical, LLC 130
Genelux Corporation 131
Nereus Pharmaceuticals, Inc. 132
Viventia Biotechnologies Inc. 133
Lytix Biopharma AS 134
Medisyn Technologies, Inc. 135
ImmuneRegen BioSciences, Inc. 136
AIMM Therapeutics B.V. 137
Cancer Therapeutics CRC Pty Ltd 138
Targa Therapeutics Corp. 139
ImmunoFrontier, Inc. 140
Bioo Therapeutics 141
Pacific Northwest Biotechnology, LLC 142
PepTx, Inc. 143
Polaris Group 144
EyeGene, Inc. 145
ToleroTech Inc. 146
ISA Pharmaceuticals B.V. 147
Gradalis Inc. 148
SentoClone AB 149
Melanoma – Therapeutics Assessment 150
Assessment by Monotherapy Products 150
Assessment by Combination Products 151
Assessment by Route of Administration 152
Assessment by Molecule Type 154
Drug Profiles 157
talminogene laherparepvec - Drug Profile 157
Product Description 157
Mechanism of Action 157
R&D Progress 157
treosulfan - Drug Profile 159
Product Description 159
Mechanism of Action 159
R&D Progress 159
GSK-2132231-A - Drug Profile 161
Product Description 161
Mechanism of Action 161
R&D Progress 161
dabrafenib + trametinib - Drug Profile 163
Product Description 163
Mechanism of Action 163
R&D Progress 163
talimogene laherparepvec - Drug Profile 165
Product Description 165
Mechanism of Action 165
R&D Progress 165
POL-103-A - Drug Profile 167
Product Description 167
Mechanism of Action 167
R&D Progress 167
Melanoma Therapeutics – Drug Profile Updates 168
Melanoma Therapeutics – Discontinued Products 171
Melanoma Therapeutics - Dormant Products 173
Asthma – Product Development Milestones 185
Featured News & Press Releases 185
May 11, 4018: Pharmaxis’ Aridol Authorised For Sale In Germany 185
Nov 12, 2012: MediciNova Announces Publication Of MN-221 Clinical Results In Journal of Asthma 185
Nov 09, 2012: Teva Pharma\'\'s Qnasl Demonstrates Efficacy Profile In Pediatric Patients With Seasonal Allergic Rhinitis In Phase III Study 186
Nov 09, 2012: Teva Pharma\'\'s Qnasl Demonstrates Efficacy Profile In Pediatric Patients With Seasonal Allergic Rhinitis In Phase III Study 187
Nov 09, 2012: NICE Draft Guidance Turns Down Novartis\'\'s Omalizumab For Treating Severe, Persistent Allergic Asthma In Adults And Children 189
Nov 06, 2012: Teva To Present New Phase III Data For Qnasl Nasal Aerosol At 2012 ACAAI Meeting 190
Oct 31, 2012: Dynavax To Initiate Phase I Studies For TLR-9 Agonist For Asthma 191
Oct 29, 2012: GSK Initiates Phase III Program For Mepolizumab In Severe Refractory Asthma 191
Oct 24, 2012: InDex Pharma Obtains Japanese Patent For New Treatment Of Steroid-Resistant Inflammation 192
Oct 22, 2012: AIM Therapeutics Announces Initiation Of AIM-102 Phase II Trial In Asthmatic Patients 193

Appendix 194
Methodology 194
Coverage 194
Secondary Research 194
Primary Research 194
Expert Panel Validation 194
Contact Us 195
Disclaimer 195

List of Table


Number of Products Under Development for Melanoma, H1 2013 12
Products under Development for Melanoma - Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Development by Companies, H1 2013 (Contd..2) 17
Number of Products under Development by Companies, H1 2013 (Contd..3) 18
Number of Products under Development by Companies, H1 2013 (Contd..4) 19
Number of Products under Development by Companies, H1 2013 (Contd..5) 20
Number of Products under Development by Companies, H1 2013 (Contd..6) 21
Number of Products under Development by Companies, H1 2013 (Contd..7) 22
Number of Products under Development by Companies, H1 2013 (Contd..8) 23
Number of Products under Investigation by Universities/Institutes, H1 2013 25
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 26
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 27
Comparative Analysis by Late Stage Development, H1 2013 28
Comparative Analysis by Mid Clinical Stage Development, H1 2013 29
Comparative Analysis by Early Clinical Stage Development, H1 2013 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 31
Products under Development by Companies, H1 2013 32
Products under Development by Companies, H1 2013 (Contd..1) 33
Products under Development by Companies, H1 2013 (Contd..2) 34
Products under Development by Companies, H1 2013 (Contd..3) 35
Products under Development by Companies, H1 2013 (Contd..4) 36
Products under Development by Companies, H1 2013 (Contd..5) 37
Products under Development by Companies, H1 2013 (Contd..6) 38
Products under Development by Companies, H1 2013 (Contd..7) 39
Products under Development by Companies, H1 2013 (Contd..8) 40
Products under Development by Companies, H1 2013 (Contd..9) 41
Products under Development by Companies, H1 2013 (Contd..10) 42
Products under Investigation by Universities/Institutes, H1 2013 43
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 44
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 45
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 46
Johnson & Johnson, H1 2013 47
Vical Incorporated, H1 2013 48
Amgen Inc., H1 2013 49
AstraZeneca PLC, H1 2013 50
Eli Lilly and Company, H1 2013 51
Viralytics Ltd., H1 2013 52
GlaxoSmithKline plc, H1 2013 53
Nektar Therapeutics, H1 2013 54
Antigenics, Inc., H1 2013 55
Inovio Biomedical Corporation, H1 2013 56
medac GmbH, H1 2013 57
Merck & Co., Inc., H1 2013 58
Lentigen Corporation, H1 2013 59
Generex Biotechnology Corporation, H1 2013 60
Plexxikon Inc., H1 2013 61
Amorfix Life Sciences Ltd., H1 2013 62
Prolexys Pharmaceuticals, Inc., H1 2013 63
Aposense Ltd., H1 2013 64
Histogen, Inc., H1 2013 65
ZIOPHARM Oncology, Inc., H1 2013 66
Novartis AG, H1 2013 67
Aphios Corporation, H1 2013 68
Daewoong Pharmaceutical Co., Ltd., H1 2013 69
Eisai Co., Ltd., H1 2013 70
Ono Pharmaceutical Co., Ltd., H1 2013 71
Pfizer Inc., H1 2013 72
SuperGen, Inc., H1 2013 73
Teva Pharmaceutical Industries Limited, H1 2013 74
Hadasit Medical Research Services & Development Ltd, H1 2013 75
Exelixis, Inc., H1 2013 76
Aduro BioTech, H1 2013 77
Alfacell Corporation, H1 2013 78
Bayer AG, H1 2013 79
MannKind Corporation, H1 2013 80
4SC AG, H1 2013 81
EpiCept Corporation, H1 2013 82
Hana Biosciences, Inc., H1 2013 83
Celldex Therapeutics, Inc., H1 2013 84
Anavex Life Sciences Corp., H1 2013 85
Lorus Therapeutics Inc, H1 2013 86
Cleveland BioLabs, Inc., H1 2013 87
Oncolytics Biotech Inc., H1 2013 88
Compugen Ltd., H1 2013 89
Patrys Limited, H1 2013 90
Curis, Inc., H1 2013 91
La Jolla Pharmaceutical Company, H1 2013 92
Green Cross Corporation, H1 2013 93
Innocell Corporation, H1 2013 94
Synta Pharmaceuticals Corp., H1 2013 95
Summit Corporation plc, H1 2013 96
Scancell Holdings Plc, H1 2013 97
MabVax Therapeutics, Inc., H1 2013 98
Antigen Express, Inc., H1 2013 99
Cancer Research Technology Limited, H1 2013 100
Digna Biotech, S.L., H1 2013 101
Oryzon, H1 2013 102
PCI Biotech Holding ASA, H1 2013 103
Antisense Pharma GmbH, H1 2013 104
Bionucleon Srl, H1 2013 105
Ambit Biosciences Corporation, H1 2013 106
Philogen S.p.A., H1 2013 107
Multimmune GmbH, H1 2013 108
Alethia Biotherapeutics Inc., H1 2013 109
Hawthorn Pharmaceuticals, Inc., H1 2013 110
MacroGenics, Inc., H1 2013 111
PDS Biotechnology Corporation, H1 2013 112
AlphaVax, Inc., H1 2013 113
Azaya Therapeutics, Inc., H1 2013 114
Iconic Therapeutics, Inc., H1 2013 115
ProNAi Therapeutics, Inc., H1 2013 116
Jennerex Biotherapeutics, Inc., H1 2013 117
Axelar AB, H1 2013 118
Pharminox Limited, H1 2013 119
Innogene Kalbiotech Pte Ltd., H1 2013 120
NovaLead Pharma Pvt. Ltd., H1 2013 121
Assessment by Monotherapy Products, H1 2013 150
Assessment by Combination Products, H1 2013 151
Assessment by Stage and Route of Administration, H1 2013 153
Assessment by Stage and Molecule Type, H1 2013 156
Melanoma Therapeutics - Drug Profile Updates 168
Melanoma Therapeutics - Discontinued Products 171
Melanoma Therapeutics - Discontinued Products (Contd..1) 172
Melanoma Therapeutics - Dormant Products 173
Melanoma Therapeutics - Dormant Products (Contd..1) 174
Melanoma Therapeutics - Dormant Products (Contd..2) 175
Melanoma Therapeutics - Dormant Products (Contd..3) 176
Melanoma Therapeutics - Dormant Products (Contd..4) 177
Melanoma Therapeutics - Dormant Products (Contd..5) 178
Melanoma Therapeutics - Dormant Products (Contd..6) 179
Melanoma Therapeutics - Dormant Products (Contd..7) 180
Melanoma Therapeutics - Dormant Products (Contd..8) 181
Melanoma Therapeutics - Dormant Products (Contd..9) 182
Melanoma Therapeutics - Dormant Products (Contd..10) 183
Melanoma Therapeutics - Dormant Products (Contd..11) 184

List of Chart


Number of Products under Development for Melanoma, H1 2013 12
Products under Development for Melanoma - Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 24
Late Stage Products, H1 2013 28
Mid Clinical Stage Products, H1 2013 29
Early Clinical Stage Products, H1 2013 30
Discovery and Pre-Clinical Stage Products, H1 2013 31
Assessment by Monotherapy Products, H1 2013 150
Assessment by Combination Products, H1 2013 151
Assessment by Route of Administration, H1 2013 152
Assessment by Stage and Route of Administration, H1 2013 153
Assessment by Molecule Type, H1 2013 154
Assessment by Stage and Molecule Type, H1 2013 155

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *